$Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma$

Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma

Background: Neuroblastic tumors (NBTs) originate from a block in the process of differentiation. Histologically, NBTs are classified in neuroblastoma (NB), ganglioneuroblastoma (GNB), and ganglioneuroma (GN). Current therapy for high-risk (HR) NB includes chemotherapy, surgery, radiotherapy, and ant...

Full description

Bibliographic Details
Main Authors:	Jaume Mora, Alicia Castañeda, Maria Cecilia Colombo, Maite Gorostegui, Fernando Gomez, Salvador Mañe, Vicente Santa-Maria, Moira Garraus, Napoleon Macias, Sara Perez-Jaume, Oscar Muñoz, Juan Pablo Muñoz, Ignasi Barber, Mariona Suñol
Format:	Article
Language:	English
Published:	MDPI AG 2021-03-01
Series:	Cancers
Subjects:	neuroblastoma anti-GD2 immunotherapy naxitamab differentiation functional MRI functional imaging
Online Access:	https://www.mdpi.com/2072-6694/13/6/1264

Similar Items

Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use—Updated Outcome Report
by: Jaume Mora, et al.
Published: (2023-04-01)

Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab
by: Amalia Varo, et al.
Published: (2023-05-01)

Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes
by: Juan Pablo Muñoz, et al.
Published: (2023-10-01)

The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies
by: Jaume Mora, et al.
Published: (2020-10-01)

Guidelines for outpatient administration of naxitamab: Experience from Atrium Health Levine Children's Hospital
by: Erin Murphy Trovillion, et al.
Published: (2024-02-01)

Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma
by: Godfrey Chi-Fung Chan, et al.
Published: (2022-02-01)

The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1
by: Adeiye A. Pilgrim, et al.
Published: (2023-12-01)

Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma
by: Fiorella Iglesias Cardenas, et al.
Published: (2021-12-01)

GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype
by: Claudia Paret, et al.
Published: (2022-12-01)

Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis
by: Michelle L. Tas, et al.
Published: (2021-09-01)

Functionalized GD2 Electrochemical Immunosensor to Diagnose Minimum Residual Disease of Bone Marrow in Neuroblastoma Effectively
by: Chong Chen, et al.
Published: (2023-10-01)

A GD2-aptamer-mediated, self-assembling nanomedicine for targeted multiple treatments in neuroblastoma theranostics
by: Liyu Zhang, et al.
Published: (2021-12-01)

Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
by: Keyel ME, et al.
Published: (2018-12-01)

Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
by: Thomas Blom, et al.
Published: (2021-02-01)

Anti-GD2 antibody and Vorinostat immunocombination therapy is highly effective in an aggressive orthotopic neuroblastoma model
by: Renske J. E. van den Bijgaart, et al.
Published: (2020-01-01)

4SCAR‐GD2‐modified T‐cell therapy in neuroblastoma with MYCN amplification: A case report with over 4‐year follow‐up data
by: Xiao Xu, et al.
Published: (2020-03-01)

Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2
by: Cristina Larrosa, et al.
Published: (2023-07-01)

Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma
by: Nicola Tumino, et al.
Published: (2021-11-01)

A Multi-Color Flow Cytometric Assay for Quantifying Dinutuximab Binding to Neuroblastoma Cells in Tumor, Bone Marrow, and Blood
by: Michelle E. Keyel, et al.
Published: (2023-09-01)

Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments
by: Leah Klingel, et al.
Published: (2022-11-01)

The Pyrazolo[3,4-<i>d</i>]Pyrimidine Derivative Si306 Encapsulated into Anti-GD2-Immunoliposomes as Therapeutic Treatment of Neuroblastoma
by: Enrico Rango, et al.
Published: (2022-03-01)

RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype
by: Maxim Sorokin, et al.
Published: (2020-05-01)

Identification of a Glycosyltransferase Signature for Predicting Prognosis and Immune Microenvironment in Neuroblastoma
by: Yongliang Sha, et al.
Published: (2022-01-01)

Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials
by: Aleksandra Wieczorek, et al.
Published: (2022-04-01)

Adaptation of the Th-MYCN Mouse Model of Neuroblastoma for Evaluation of Disseminated Disease
by: Seyed M. Rahavi, et al.
Published: (2023-07-01)

Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience
by: Nur Olgun, et al.
Published: (2022-12-01)

Novel Gd(OH)3, GdOOH and Gd2O3 Nanorods: Microwave-Assisted Hydrothermal Synthesis and Optical Properties
by: Maciel Salomão de Almeida, et al.
Published: (2016-08-01)

Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies
by: Irina V. Kholodenko, et al.
Published: (2019-10-01)

Co-Administration of Fendiline Hydrochloride Enhances Chemotherapeutic Efficacy of Cisplatin in Neuroblastoma Treatment
by: Antonella Brizzolara, et al.
Published: (2020-11-01)

Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy
by: Holger N. Lode, et al.
Published: (2023-06-01)

Immune Monitoring during Therapy Reveals Activitory and Regulatory Immune Responses in High-Risk Neuroblastoma
by: Celina L. Szanto, et al.
Published: (2021-04-01)

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
by: Bassel Nazha, et al.
Published: (2020-07-01)

Novel drug - dinutuximab for high-risk neuroblastoma
by: Supriya Kushwah, et al.
Published: (2018-01-01)

B3GALT4 remodels the tumor microenvironment through GD2-mediated lipid raft formation and the c-met/AKT/mTOR/IRF-1 axis in neuroblastoma
by: Yong-Liang Sha, et al.
Published: (2022-10-01)

The microstructure and mechanical properties of Mg-Gd-Y-Zn-Zr system and Mg-Gd-Y-Zr system alloys by RUE deformation
by: Leichen Jia, et al.
Published: (2021-01-01)

Los Neuroblastomas
by: Jean Michon, et al.
Published: (2019-09-01)

Olfactory Neuroblastoma
by: Ian C. Bickle
Published: (2016-06-01)

Olfactory Neuroblastoma
by: Jose M. Carnate
Published: (2010-12-01)

AC-265347 Inhibits Neuroblastoma Tumor Growth by Induction of Differentiation without Causing Hypocalcemia
by: Eliana Gonçalves-Alves, et al.
Published: (2022-04-01)

The biological role and immunotherapy of gangliosides and GD3 synthase in cancers
by: Shangqi Cao, et al.
Published: (2023-02-01)